SA520411112B1 - عملية محسّنة لتحضير مشتقات أمينو بيريميدين - Google Patents
عملية محسّنة لتحضير مشتقات أمينو بيريميدينInfo
- Publication number
- SA520411112B1 SA520411112B1 SA520411112A SA520411112A SA520411112B1 SA 520411112 B1 SA520411112 B1 SA 520411112B1 SA 520411112 A SA520411112 A SA 520411112A SA 520411112 A SA520411112 A SA 520411112A SA 520411112 B1 SA520411112 B1 SA 520411112B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- preparing
- improved process
- aminopyrimidine derivatives
- protein kinases
- present
- Prior art date
Links
- 150000005005 aminopyrimidines Chemical class 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108060006633 protein kinase Proteins 0.000 abstract 2
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 108060006698 EGF receptor Proteins 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/22—Tin compounds
- C07F7/2284—Compounds with one or more Sn-N linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Catalysts (AREA)
Abstract
يوفر الاختراع الحالي عملية محسّنة لتحضير مشتقات أمينو بيريميدين أو أملاح منه مقبولة صيدلانيًا تتميز بنشاط تثبيطي انتقائي ضد كينازات البروتين، وخاصة ضد كينازات البروتين لمستقبلات عوامل النمو البشروية الطافرة. ويوفر الاختراع الحالي أيضًا مركبات وسيطة جديدة مفيدة للعملية المذكورة ولعمليات من أجل تحضيرها.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170096212 | 2017-07-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA520411112B1 true SA520411112B1 (ar) | 2022-02-21 |
Family
ID=65040211
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA520411112A SA520411112B1 (ar) | 2017-07-28 | 2020-01-21 | عملية محسّنة لتحضير مشتقات أمينو بيريميدين |
| SA522431428A SA522431428B1 (ar) | 2017-07-28 | 2020-01-21 | عملية محسّنة لتحضير مشتقات أمينو بيريميدين |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA522431428A SA522431428B1 (ar) | 2017-07-28 | 2020-01-21 | عملية محسّنة لتحضير مشتقات أمينو بيريميدين |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US10889578B2 (ar) |
| EP (1) | EP3658552B1 (ar) |
| JP (2) | JP7228562B2 (ar) |
| KR (1) | KR102688084B1 (ar) |
| CN (2) | CN111315742B (ar) |
| AU (2) | AU2018308038B2 (ar) |
| BR (1) | BR112020001278A2 (ar) |
| CA (1) | CA3070069C (ar) |
| CO (1) | CO2020000374A2 (ar) |
| DK (1) | DK3658552T3 (ar) |
| EA (1) | EA202090383A1 (ar) |
| ES (1) | ES2962961T3 (ar) |
| FI (1) | FI3658552T3 (ar) |
| HR (1) | HRP20231191T1 (ar) |
| HU (1) | HUE063533T2 (ar) |
| IL (2) | IL271973B (ar) |
| LT (1) | LT3658552T (ar) |
| MA (1) | MA49700B1 (ar) |
| MD (1) | MD3658552T2 (ar) |
| MX (2) | MX393995B (ar) |
| MY (1) | MY198379A (ar) |
| PH (1) | PH12020500059A1 (ar) |
| PL (1) | PL3658552T3 (ar) |
| PT (1) | PT3658552T (ar) |
| RS (1) | RS64654B1 (ar) |
| SA (2) | SA520411112B1 (ar) |
| SG (1) | SG11201913517UA (ar) |
| SI (1) | SI3658552T1 (ar) |
| SM (1) | SMT202300339T1 (ar) |
| UA (1) | UA125317C2 (ar) |
| WO (1) | WO2019022485A1 (ar) |
| ZA (1) | ZA202001250B (ar) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201913517UA (en) | 2017-07-28 | 2020-02-27 | Yuhan Corp | Improved process for preparing aminopyrimidine derivatives |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| US11879013B2 (en) | 2019-05-14 | 2024-01-23 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
| JP7783182B2 (ja) | 2020-02-12 | 2025-12-09 | ヤンセン バイオテツク，インコーポレーテツド | ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療 |
| US12138351B2 (en) | 2020-04-14 | 2024-11-12 | Janssen Biotech, Inc. | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof |
| US11780824B2 (en) * | 2020-12-16 | 2023-10-10 | Scinopharm Taiwan, Ltd. | Process for preparing osimertinib or a salt thereof |
| CN116199701A (zh) * | 2023-02-27 | 2023-06-02 | 安徽中医药大学 | 一种基于分子内自由基环加成制备吡唑并恶嗪草酮类化合物及其制备方法 |
| CA3228195A1 (en) | 2023-05-23 | 2025-06-30 | Janssen Biotech, Inc. | Methods for treatment of non-small cell lung cancer (nsclc) |
| AU2024337472A1 (en) | 2023-09-05 | 2026-04-16 | Janssen Biotech, Inc. | Methods of treating non-small cell lung cancer |
| WO2026042017A1 (en) | 2024-08-19 | 2026-02-26 | Janssen Biotech, Inc. | Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc) |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| AR037438A1 (es) | 2001-11-27 | 2004-11-10 | Wyeth Corp | 3-cianoquinolinas como inhibidores de egf-r y her2 quinasas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| AU2005309019A1 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors |
| US20060270600A1 (en) | 2005-05-26 | 2006-11-30 | Eisuke Mekada | Anti-cancer agents |
| TW200736232A (en) | 2006-01-26 | 2007-10-01 | Astrazeneca Ab | Pyrimidine derivatives |
| ES2555803T3 (es) | 2006-10-23 | 2016-01-08 | Cephalon, Inc. | Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met |
| TW200840581A (en) | 2007-02-28 | 2008-10-16 | Astrazeneca Ab | Novel pyrimidine derivatives |
| WO2008124085A2 (en) | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
| NZ603525A (en) * | 2008-06-27 | 2015-02-27 | Celgene Avilomics Res Inc | Pyrimidine based compound and uses thereof |
| EP2488503A1 (en) | 2009-10-12 | 2012-08-22 | Myrexis, Inc. | Amino - pyrimidine compounds as inhibitors of tbkl and/or ikk epsilon |
| EA024729B1 (ru) * | 2009-11-13 | 2016-10-31 | Джиноско | Киназные ингибиторы |
| JP5802676B2 (ja) | 2009-12-04 | 2015-10-28 | センワ バイオサイエンシズ インコーポレイテッド | Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物 |
| MY170236A (en) | 2010-10-06 | 2019-07-11 | Glaxosmithkline Llc | Benzimidazole derivatives as pi3 kinase inhibitors |
| WO2012061303A1 (en) | 2010-11-01 | 2012-05-10 | Avila Therapeutics, Inc. | Heteroaryl compounds and uses thereof |
| UA112425C2 (uk) | 2010-12-13 | 2016-09-12 | Еррей Біофарма Інк. | ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ |
| EP4119551A1 (en) | 2011-07-27 | 2023-01-18 | Astrazeneca AB | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
| TW201332989A (zh) | 2011-12-23 | 2013-08-16 | Millennium Pharm Inc | 雜芳基化合物及其用途 |
| BR112014015720B1 (pt) | 2011-12-30 | 2020-03-17 | Hanmi Pharm. Co., Ltd. | Derivados de tieno[3,2-d]pirimidina, composição farmacêutica e uso dos mesmos para a prevenção ou tratamento de uma doença causada por ativação anormal de uma proteína quinase |
| CN104860891B (zh) | 2014-02-25 | 2017-06-30 | 上海海雁医药科技有限公司 | 芳氨基嘧啶类化合物及其应用以及由其制备的药物组合物和药用组合物 |
| JP6468611B2 (ja) | 2014-05-13 | 2019-02-13 | アリアド ファーマシューティカルズ， インコーポレイテッド | キナーゼ阻害のためのヘテロアリール化合物 |
| WO2015188777A1 (en) | 2014-06-12 | 2015-12-17 | Shanghai Fochon Pharmaceutical Co Ltd | Certain protein kinase inhibitors |
| HUE054848T2 (hu) | 2014-10-13 | 2021-09-28 | Yuhan Corp | Vegyületek és készítmények EGFR mutáns kináz aktivitás módosítására |
| CN104788427B (zh) * | 2015-02-05 | 2017-05-31 | 上海泓博智源医药股份有限公司 | 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用 |
| AR102263A1 (es) | 2015-10-14 | 2017-02-15 | Yuhan Corp | Compuestos y composiciones para la modulación de las actividades quinasa del receptor de egf mutante |
| AR111469A1 (es) | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| DE102017212159A1 (de) | 2017-07-14 | 2019-01-17 | Krones Aktiengesellschaft | Verfahren und Vorrichtung zur Handhabung von Stückgütern, Artikeln und/oder Gebinden |
| WO2019022486A1 (en) | 2017-07-28 | 2019-01-31 | Yuhan Corporation | NOVEL INTERMEDIATES USEFUL FOR SYNTHESIZING AMINOPYRIMIDINE DERIVATIVES, PROCESS FOR PREPARING THE SAME, AND PROCESS FOR PREPARING AMINOPYRIMIDINE DERIVATIVES THEREWITH |
| MY201038A (en) * | 2017-07-28 | 2024-01-31 | Yuhan Corp | Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same |
| SG11201913517UA (en) | 2017-07-28 | 2020-02-27 | Yuhan Corp | Improved process for preparing aminopyrimidine derivatives |
| CN108826170A (zh) | 2018-06-26 | 2018-11-16 | 深圳市远润欣电子有限公司 | 局部全般照明的模式、控制方法及台灯 |
-
2018
- 2018-07-25 SG SG11201913517UA patent/SG11201913517UA/en unknown
- 2018-07-25 HR HRP20231191TT patent/HRP20231191T1/hr unknown
- 2018-07-25 RS RS20230834A patent/RS64654B1/sr unknown
- 2018-07-25 SI SI201830998T patent/SI3658552T1/sl unknown
- 2018-07-25 FI FIEP18837360.9T patent/FI3658552T3/fi active
- 2018-07-25 LT LTEPPCT/KR2018/008379T patent/LT3658552T/lt unknown
- 2018-07-25 EA EA202090383A patent/EA202090383A1/ru unknown
- 2018-07-25 PL PL18837360.9T patent/PL3658552T3/pl unknown
- 2018-07-25 DK DK18837360.9T patent/DK3658552T3/da active
- 2018-07-25 KR KR1020180086376A patent/KR102688084B1/ko active Active
- 2018-07-25 UA UAA202001303A patent/UA125317C2/uk unknown
- 2018-07-25 SM SM20230339T patent/SMT202300339T1/it unknown
- 2018-07-25 ES ES18837360T patent/ES2962961T3/es active Active
- 2018-07-25 AU AU2018308038A patent/AU2018308038B2/en active Active
- 2018-07-25 EP EP18837360.9A patent/EP3658552B1/en active Active
- 2018-07-25 CN CN201880048638.9A patent/CN111315742B/zh active Active
- 2018-07-25 MY MYPI2020000438A patent/MY198379A/en unknown
- 2018-07-25 WO PCT/KR2018/008379 patent/WO2019022485A1/en not_active Ceased
- 2018-07-25 PT PT188373609T patent/PT3658552T/pt unknown
- 2018-07-25 US US16/633,684 patent/US10889578B2/en active Active
- 2018-07-25 CA CA3070069A patent/CA3070069C/en active Active
- 2018-07-25 MX MX2020001041A patent/MX393995B/es unknown
- 2018-07-25 CN CN202310702453.8A patent/CN116987112B/zh active Active
- 2018-07-25 MA MA49700A patent/MA49700B1/fr unknown
- 2018-07-25 BR BR112020001278-5A patent/BR112020001278A2/pt unknown
- 2018-07-25 JP JP2020504203A patent/JP7228562B2/ja active Active
- 2018-07-25 MX MX2022008743A patent/MX2022008743A/es unknown
- 2018-07-25 HU HUE18837360A patent/HUE063533T2/hu unknown
- 2018-07-25 IL IL271973A patent/IL271973B/en unknown
- 2018-07-25 MD MDE20200593T patent/MD3658552T2/ro unknown
-
2020
- 2020-01-07 PH PH12020500059A patent/PH12020500059A1/en unknown
- 2020-01-15 CO CONC2020/0000374A patent/CO2020000374A2/es unknown
- 2020-01-21 SA SA520411112A patent/SA520411112B1/ar unknown
- 2020-01-21 SA SA522431428A patent/SA522431428B1/ar unknown
- 2020-02-27 ZA ZA2020/01250A patent/ZA202001250B/en unknown
- 2020-12-08 US US17/115,037 patent/US11286253B2/en active Active
-
2022
- 2022-03-25 US US17/704,718 patent/US11708362B2/en active Active
- 2022-04-24 IL IL292429A patent/IL292429B2/en unknown
- 2022-05-03 AU AU2022202936A patent/AU2022202936B2/en active Active
- 2022-11-18 JP JP2022184867A patent/JP7539451B2/ja active Active
-
2023
- 2023-06-02 US US18/328,267 patent/US12187714B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA520411112B1 (ar) | عملية محسّنة لتحضير مشتقات أمينو بيريميدين | |
| SA520411120B1 (ar) | مركبات وسيطة مبتكرة مفيدة لتركيب مشتقات الأمينوبيريميدين، وعملية لتحضير هذه المركبات الوسيطة، وعملية لتحضير مشتقات الأمينوبيريميدين باستخدام هذه المركبات | |
| PH12020500093A1 (en) | Intermediates useful for the synthesis of a selective inhibitor against protein kinase and processes for preparing the same | |
| ZA202202097B (en) | Amino pyrimidine ssao inhibitors | |
| AU2018271990A1 (en) | Covalent inhibitors of KRAS | |
| MX393879B (es) | Métodos de preparación de niraparib. | |
| PH12017550004A1 (en) | Heterocyclic derivatives and use thereof | |
| CA2983481A1 (en) | Janus kinase inhibitor | |
| LT3985000T (lt) | 2,4-dipakeistasis pirimidino darinys, jo gamybos būdas ir panaudojimas | |
| SG11201906435SA (en) | Pyrimidine compound and pharmaceutical use thereof | |
| WO2015111085A8 (en) | Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof | |
| AU2018375456A1 (en) | Thieno(3,2-d)pyrimidine compound having inhibitory activity for protein kinase | |
| AU2019248350A8 (en) | Process for making sarecycline hydrochloride | |
| WO2018193415A9 (en) | Process for the preparation of pirlindole enantiomers and its salts | |
| HK40013334A (en) | Processes for preparing ag-10, its intermediates, and salts thereof | |
| UA123593U (uk) | 2-(7-ФУРАН-21-ІЛ-2-МОРФОЛІН-41-ІЛ-4-ОКСО-4Н-ТІАЗОЛО[4,5-d]ПІРИДАЗИН-5-ІЛ)-N-НАФТАЛІН-1-ІЛАЦЕТАМІД, ЩО МАЄ ПРОТИПУХЛИННУ АКТИВНІСТЬ |